|1.||Firsova, L D: 3 articles (01/2010 - 01/2009)|
|2.||Masharova, A A: 3 articles (01/2010 - 01/2009)|
|3.||Bordin, D S: 3 articles (01/2010 - 01/2009)|
|4.||Kozhurina, T S: 3 articles (01/2010 - 01/2009)|
|5.||Wilkinson, J: 2 articles (10/2015 - 03/2014)|
|6.||Kahrilas, P J: 2 articles (09/2014 - 07/2011)|
|7.||Pandolfino, J E: 2 articles (09/2014 - 07/2011)|
|8.||Roman, S: 2 articles (09/2014 - 07/2011)|
|9.||Dettmar, Peter W: 2 articles (01/2012 - 02/2009)|
|10.||Strugala, Vicki: 2 articles (01/2012 - 02/2009)|
|1.||Gastroesophageal Reflux (GERD)
01/01/2010 - "Was conducted a muIticenter study VIA APIA, in which the impact of gaviscon forte (suspension) on symptoms, general state and quality of life of 148 patients (male 53, female 95, age 42.9 +/- 15.6) with gastroesophageal reflux disease (GERD) were investigated. "
01/01/1975 - "A double-blind controlled trial of 'Gaviscon' in patients with symptomatic gastro-oesophageal reflux."
10/01/1972 - "Trial of gaviscon in the treatment of gastro-oesophageal reflux of infancy."
10/01/2015 - "Mean RDQ GERD scores: 2.51 for Gaviscon DA and 2.50 for placebo at baseline; 1.25 for Gaviscon DA and 1.46 for placebo post treatment. "
03/01/2014 - "Gaviscon DA decreases reflux and dyspeptic symptoms in GERD patients compared with matched placebo and has a favourable benefit-risk balance. "
04/01/2003 - "An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy."
01/01/2009 - "Heartburn was relieved in 3.3 minutes in all patients after a single dose of Gaviscon, and in 3.6 minutes in 51 (98.1%) patients who have received a single dose of Gaviscon forte. "
01/01/2012 - "The study was a multicentre, prospective, open-label, and baseline-controlled study of Liquid Gaviscon (LG) in the treatment of heartburn in pregnant women with current symptoms of heartburn and/or reflux requiring treatment (recruited 144). "
04/01/2003 - "This study investigated the efficacy and safety of a novel reflux suppressant, Gaviscon Advance, in the treatment of heartburn during pregnancy. "
01/01/2010 - "Gaviscon forte recommended as drug of choice in initial treatment for the first time visited patient with heartburn before endoscopy and for pathogenetic treatment of typical reflux syndrome."
03/01/2014 - "The effect of Gaviscon DA on reflux and dyspepsia symptoms has not yet been demonstrated with a modern trial design. "
01/01/1979 - "In a multicentre open study, Liquid Gaviscon was shown to give effective relief of heartburn and dyspepsia in over 82% of patients. "
01/01/1979 - "The symptomatic treatment of heartburn and dyspepsia with Liquid Gaviscon: a multicentre general practitioner study."
10/01/2015 - "Gaviscon DA was statistically superior to placebo in reducing GERD and dyspepsia RDQ scores [least-squares mean (LSM) difference: GERD -0.21, P < 0.0001; dyspepsia -0.18, P = 0.0004], despite a substantial placebo response. "
01/01/2010 - "[Using gaviscon preparation for relief of esophageal, extraesophageal syndromes and functional dyspepsia in elderly patients with GERD]."
06/10/1964 - "[TREATMENT WITH GAVISCON IN HIATUS HERNIA. "
01/01/1980 - "An open study was carried out in 37 patients, with chronic, moderate to severe gastric or bilious reflux associated with hiatus hernia or subsequent to gastro-oesophageal surgery, to assess the effectiveness of an alginate/antacid combination product ('Gastrocote'). "
04/24/1976 - "A double-blind crossover trial of Gaviscon (alginate/alginic acid plus antacid) versus standard antacid is reported in 20 patients with symptomatic hiatus hernia. "
|5.||Duodenal Ulcer (Curling's Ulcer)
|1.||alginic acid (sodium alginate)